Neubewertung nach Fristablauf: Urothelkarzinom, PD-L1-Expression ≥ 1 %, adjuvante Therapie
G-BA action
final resolution
2026-06-04
Evidence-checked summary
The G-BA issued a final resolution on 2026-06-04. The official page states that it took effect as follows: 04.06.2026. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Official case record
No inferred stages
Consultation record
2026-04-27
53 parsed turns
Oral hearing: Nivolumab (Neubewertung nach Fristablauf: Urothelkarzinom, PD-L1-Expression ≥ 1 %, adjuvante Therapie)
Official Wortprotokoll · 11 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A25-154
matched
Nivolumab (urothelial carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Official assessment PDF · 138 pages
G-BA decisions
2026-06-04
final resolution
The G-BA issued a final resolution on 2026-06-04. The official page states that it took effect as follows: 04.06.2026. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
2 official documents · 3 cited claims
Official sources